NextGen Pulmocore 12 gene panel (SP142)** Price
What is a NextGen Pulmocore 12 Gene Panel (SP142)?
The NextGen Pulmocore 12 gene panel (SP142) is an advanced diagnostic test that uses Next-Generation Sequencing (NGS) technology to analyse the genetic makeup of lung cancer cells. This test examines tumour tissue obtained through a biopsy to identify specific genetic changes in 12 key genes and measures PD-L1 protein levels.
The test helps doctors create personalised treatment plans for patients with lung cancer, particularly non-small cell lung cancer (NSCLC), by identifying genetic mutations that can guide targeted therapy decisions.
What does the NextGen Pulmocore 12 gene panel (SP142) measure?
This comprehensive genetic screening test measures two critical aspects of lung cancer to guide treatment decisions:
- Actionable Genetic Mutations - Checks for alterations in 12 specific genes known to drive lung cancer growth, including EGFR, ALK, ROS1, and KRAS, allowing doctors to use targeted therapy drugs.
- PD-L1 Protein Expression - Measures the level of PD-L1 protein using the SP142 assay to determine if patients may benefit from immunotherapy treatment.
- Gene Fusions - Detects structural changes in genes like ALK, RET, ROS1, and NTRK that can inform targeted treatment options.
- Copy Number Variations - Identifies MET amplification, which may indicate specific therapeutic approaches.
NextGen Pulmocore 12 Gene Panel (SP142): Who Needs It and Why It's Done
What Symptoms May Call for a NextGen Pulmocore 12 Gene Panel (SP142)?
This panel is not ordered based on symptoms alone but follows a lung cancer diagnosis. Common symptoms that might lead a doctor to suspect lung cancer include:
- Persistent cough that doesn't go away or gets worse
- Coughing up blood or rust-coloured sputum
- Chest pain that worsens with deep breathing or coughing
- Shortness of breath or wheezing
- Hoarseness of voice
- Unexplained weight loss and loss of appetite
- Feeling tired or weak
Who should get a NextGen Pulmocore 12 Gene Panel (SP142)?
This test is specifically recommended for certain patient groups:
- Patients who are already diagnosed with non-small cell lung cancer (NSCLC).
- Individuals with advanced or metastatic NSCLC (cancer that has spread).
- Patients preparing to start their primary cancer treatment.
- Those requiring personalised treatment planning based on tumour genetics.
Why is a NextGen Pulmocore 12 gene panel (SP142) done?
This test enables precision oncology by identifying specific genetic alterations in your tumour tissue. It helps your oncologist select the most effective personalised treatment approach rather than using standard chemotherapy for all patients.
Importance of a NextGen Pulmocore 12 gene panel (SP142)
The NextGen Pulmocore 12 gene panel (SP142) represents the foundation of precision oncology for lung cancer treatment. This genetic screening allows doctors to match patients with targeted therapies that specifically attack cancer cells with particular genetic mutations, rather than using a one-size-fits-all approach.
By identifying specific genetic alterations and PD-L1 expression levels, this test helps oncologists select the most effective treatments, potentially leading to better patient outcomes, improved survival rates, and fewer side effects compared to traditional chemotherapy. The test has transformed lung cancer management by enabling personalised medicine approaches that consider each patient's unique tumour characteristics.
NextGen Pulmocore 12 gene panel (SP142) Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Pulmocore 12 gene panel (SP142)?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the NextGen Pulmocore 12 gene panel (SP142), choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is home sample collection for NextGen Pulmocore 12 gene panel (SP142) available near you?
No, Metropolis Healthcare does not provide home sample collection for the NextGen Pulmocore 12 gene panel (SP142), as it requires tumour tissue from a biopsy procedure performed in a medical facility. However, once your tissue sample is collected through biopsy at a healthcare facility, our trained professionals can coordinate the secure transport of your sample to our NABL & CAP accredited pathology lab.
How Long Does It Take to Get a NextGen Pulmocore 12 gene panel (SP142) Report?
Reports are typically available after 12 days, once the sample has reached the lab.
Note: Reporting time may vary depending on your location.
Where can I see or get NextGen Pulmocore 12 gene panel (SP142) results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Pulmocore 12 Gene Panel (SP142) Results
What Your NextGen Pulmocore 12 Gene Panel (SP142) Results May Indicate
The following table provides guidance on understanding your genetic screening results:
|
Parameters |
Result Type |
Positive/Detected |
Negative/Not Detected |
|
Hotspot Mutations (EGFR, ALK, BRAF, etc.) |
Mutation Status |
Specific mutation found - targeted therapy may be available |
No mutation detected - standard treatment approach |
|
Gene Fusions (ALK, ROS1, RET, NTRK) |
Fusion Status |
Fusion detected - specific targeted drugs available |
No fusion found - alternative treatment options |
|
MET Amplification |
Copy Number |
Amplification present - MET inhibitors may be effective |
Normal copy number - standard treatment approach |
Conditions that May Affect NextGen Pulmocore 12 Gene Panel (SP142) Accuracy
Several factors can influence your test results and should be discussed with your healthcare team:
- Tissue quality - Poor tissue preservation or insufficient tumour content may affect results.
- Sample storage conditions - Improper storage temperature or prolonged storage can degrade genetic material.
- Tumour heterogeneity - Different areas of the same tumour may have varying genetic profiles.
- Previous treatments - Prior chemotherapy or radiation may alter the genetic landscape of tumour tissue.
- Sample contamination - Presence of normal tissue or other contaminants in the biopsy sample.
- Technical factors - Laboratory processing conditions and equipment calibration can impact accuracy.
How is a NextGen Pulmocore 12 Gene Panel (SP142) Done?
The genetic analysis process involves several carefully coordinated steps:
- Tissue collection - A biopsy sample is obtained from your lung tumour during a medical procedure.
- Sample preparation - The tissue is processed and embedded in paraffin to preserve genetic material.
- DNA extraction - Genetic material is carefully extracted from the tumour cells.
- Library preparation - The DNA is prepared for sequencing using specialised laboratory techniques.
- Next-generation sequencing - Advanced sequencing technology analyses the genetic code.
- Data analysis - Sophisticated software identifies mutations, fusions, and protein expression levels.
- Report generation - Results are compiled into a comprehensive report for your oncologist.
How Should You Prepare for a NextGen Pulmocore 12 Gene Panel (SP142)?
Preparation for this test focuses on the tissue sample collection procedure:
- No fasting required - You can eat and drink normally before the biopsy procedure.
- Medication review - Discuss all current medications with your doctor before the biopsy.
- Medical history - Provide a complete clinical history and previous histopathology reports.
- Follow biopsy instructions - Your doctor will provide specific preparation guidelines for the tissue collection procedure.
- Arrange transportation - Plan for someone to accompany you if sedation is used during the biopsy.
Diseases that a NextGen Pulmocore 12 Gene Panel (SP142) Can Help Detect
This comprehensive genetic screening test helps identify and guide treatment for several health conditions:
- Non-Small Cell Lung Cancer (NSCLC) - Primary indication for this genetic panel.
- Lung adenocarcinoma - A common type of lung cancer with targetable mutations.
- Lung squamous cell carcinoma - Another form of NSCLC that may benefit from targeted therapy.
- Metastatic lung cancer - Advanced cancer that has spread to other parts of the body.
- Treatment-resistant lung cancer - Cases where standard therapies have not been effective.
- Recurrent lung cancer - Cancer that returns after initial treatment.
NextGen Pulmocore 12 Gene Panel (SP142)/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive cancer screening packages and tests that are available to support comprehensive lung cancer diagnosis and management:
|
Test/Package Name |
Purpose/Highlights |
|
Comprehensive screening for various cancer biomarkers |
|
|
Specialised panel for non-small cell lung cancer diagnosis |
|
|
Focused genetic testing for common lung cancer mutations |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.